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Summary
Background In adults with HIV treated with antiretroviral drug regimens from within the three original drug classes 
(nucleoside or nucleotide reverse transcriptase inhibitors [NRTIs], non-NRTIs [NNRTIs], and protease inhibitors), 
virological failure occurs slowly, suggesting that long-term virological suppression can be achieved in most people, 
even in areas where access is restricted to drugs from these classes. It is unclear whether this is the case for 
children, the group who will need to maintain viral suppression for longest. We aimed to determine the rate and 
predictors of triple-class virological failure to the three original drugs classes in children.
Methods In the Collaboration of Observational HIV Epidemiological Research Europe, the rate of triple-class 
virological failure was studied in children infected perinatally with HIV who were aged less than 16 years, starting 
antiretroviral therapy (ART) with three or more drugs, between 1998 and 2008. We used Kaplan-Meier and Cox 
regression methods to investigate the risk and predictors of triple-class virological failure after ART initiation.
Findings Of 1007 children followed up for a median of 4·2 (IQR 2·4–6·5) years, 237 (24%) were triple-class exposed 
and 105 (10%) had triple-class virological failure, of whom 29 never had a viral-load measurement less than 
500 copies per mL. Incidence of triple-class virological failure after ART initiation increased with time, and risk by 
5 years after ART initiation was 12·0% (95% CI 9·4–14·6). In multivariate analysis, older age at ART initiation was 
associated with increased risk of failure (p=0·02). Of 686 children starting ART with NRTIs and either a NNRTI or 
ritonavir-boosted protease inhibitor, the rate of failure was higher than in adults with heterosexually transmitted HIV 
(hazard ratio 2·2 [95% CI 1·6–3·0, p<0·0001]).
Interpretation Findings highlight the challenges of attaining long-term viral suppression in children who will be 
taking life-long ART. Early identiﬁ cation of children not responding to ART, adherence support, particularly for 
children and adolescents aged 13 years or older starting ART, and ART simpliﬁ cation strategies are all needed to 
attain and sustain virological suppression.
Funding UK Medical Research Council award G0700832.
Introduction
Antiretroviral therapy (ART) has strikingly improved the 
prognosis for children with HIV, greatly reducing 
morbidity and mortality.1–3 However, a major challenge 
for treatment of these children is to minimise virological 
failure and development of drug resistance, so that 
treatment options continue to be available through 
adolescence and adulthood.
During the past decade, paediatric ART guidelines 
recommended an age-related CD4 percentage or count 
threshold for initiation of ART in infants and children.4 
However, in view of results from the Children with HIV 
Early Antiretroviral Therapy (CHER) trial and other 
evidence,5,6 paediatric ART guidelines now unanimously 
advocate initiation of ART early in infancy because of the 
high risk of disease progression.7–9 Even if ART is not 
started early, vertically infected children face many more 
years of ART than do adults. A serious challenge for 
children with HIV, as for any chronic illness, is 
maintaining long-term adherence to treatment regimens, 
and thus virological suppression and prevention of 
emergence of resistance.10–14 However, experience with 
these children suggests that, with present treatment 
strategies, adherence rates are frequently less than 
optimum,15,16 which combined with the increased 
potential for inadequate drug dosing,17,18 contribute to 
appreciable risk of children acquiring multidrug-
resistant HIV before adulthood.
As for adults, most paediatric ART regimens include 
drugs from one or more of the original three ART classes: 
nucleoside or nucleotide reverse transcriptase inhibitors 
(NRTI), non-NRTIs (NNRTI), and protease inhibitors. 
The availability of drugs from the new classes (integrase 
and entry inhibitors) remains limited by the lag in 
availability of appropriate formulations and pharma-
cokinetic data for children, and, in developing countries, 
high drug costs.18 Virological failure of the three original 
drug classes during childhood will severely limit future 
treatment options; therefore, the rate of triple-class 
virological failure should be monitored, to estimate the 
number of children transferring to adult care in probable 
need of treatment with new drugs.
We aimed to determine the rate and predictors of 
triple-class virological failure to the three original drug 
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classes in children within the Collaboration of 
Observational HIV Epidemiological Research Europe 
(COHERE).19 The study forms part of the Pursuing 
Later Treatment Options II (PLATO II) project; an 
analysis of triple-class virological failure in adults from 
this project has been published.20
Methods
Study design
14 cohorts with paediatric data in COHERE submitted 
data in a standardised format21 to one of two regional 
coordinating centres, where error checks were done 
before data were merged. Children appearing in more 
than one cohort were identiﬁ ed, and duplicate records 
removed. This analysis (of data merged in 2008) was 
restricted to children perinatally infected with HIV 
aged less than 16 years who started ART from 1998 
onwards with an initial regimen of two or more NRTIs 
and either a NNRTI or a protease inhibitor (ritonavir-
boosted or unboosted), or three NRTIs only (children 
exposed to ART for the prevention of mother-to-child 
transmission before starting one of the above regimens 
were included). Unlike in the adult analysis,20 children 
starting initial regimens with unboosted protease 
inhibitors, more than two NRTIs with a NNRTI or 
protease inhibitor, and three NRTIs only were included 
to mirror the regimens commonly prescribed to 
children in the past decade.22 A second analysis was 
done to mirror the adult analysis. Children were 
followed up from the start of ART to their last viral-load 
measurement. Because the deﬁ nition of virological 
failure used in this study required 4 months of use of a 
drug, children were included only if they had at least 
4 months (122 days) of follow-up. Time spent oﬀ  ART 
(after ART had been started) was included as follow-up. 
Children were said to have interrupted ART if they 
stopped all antiretrovirals.
Data extraction
The main outcome in this study was triple-class virological 
failure, deﬁ ned as virological failure to at least two NRTIs, 
one NNRTI, and one protease inhibitor. We deﬁ ned 
virological failure of a drug as one viral-load measurement 
of greater than 500 copies per mL after at least 4 months of 
continuous use of that drug, regardless of concomitant 
use of other drugs in that period. We did sensitivity 
analyses using two variations of this deﬁ nition: ﬁ rst, 
6 months instead of 4 months of continuous drug use; 
second, viral load above 500 copies per mL after 4 months 
continuous use had to be conﬁ rmed by a second viral load 
value greater than 500 copies per mL while still on or 
followed by discontinuation of the drug.
To enable comparisons of the rate of triple-class 
virological failure in children with that of adults,20 and to 
represent rates of failure in children starting currently 
recommended regimens, we did a second analysis to 
restrict the population to children starting ART with an 
initial regimen of two or three NRTIs and either a NNRTI 
or a ritonavir-boosted protease inhibitor (ie, those for 
whom the initial ART regimen included an unboosted 
protease inhibitor, or three NRTIs, were excluded). 
Initial regimen
Main analysis
Comparison
with adults
NNRTI + 2 NRTI
NNRTI + 3 NRTI
PI/r + 2 or 3 NRTI
uPI + 2 or 3 NRTI
3 NRTIs
NNRTI + 2 NRTI
NNRTI + 3 NRTI
PI/r + 2 or 3 NRTI
NNRTI + 2 NRTI
PI/r + 2 NRTI
Children
Adults
TCVF deﬁnition
Failure of
• 2 NRTIs
• 1 NNRTI
• 1 PI
Failure of
• 2 NRTIs
• 1 NNRTI
• 1 PI/r
For more on data merging see 
http://www.cphiv.dk/COHERE/
StudyDocuments/tabid/298/
Default.aspx
Figure 1: Inclusion criteria for initial regimens and deﬁ nition of triple-class 
virological failure in the main analysis and the comparison of children 
with adults
TCVF=triple-class virological failure. NRTI=nucleoside or nucleotide reverse 
transcriptase inhibitors. NNRTI=non-NRTI. PI/r=ritonavir-boosted protease 
inhibitor. PI=protease inhibitor. uPI=unboosted protease inhibitor.
Number of children (n=1007) Median follow-up person-years 
Sex
Boy 510 (51%) 3·9
Girl 497 (50%) 3·6
Age at start of ART (years)
<2 350 (35%) 4·1
2–4 202 (20%) 4·3
5–9 265 (26%) 4·0
10–15 190 (19%) 2·9
Median (IQR) 4·2 (0·9–8·5) ··
Year of ART initiation
1998–2000 368 (37%) 6·8
2001–2003 363 (36%) 3·9
2004–2007 276 (27%) 1·7
Previous ART exposure for prevention of mother-to-child transmission*
No 937 (93%) 3·9
Yes 70 (7%) 3·1
Initial regimen
NNRTI + 2 NRTIs 467 (46%) 3·0
NNRTI + 3 NRTIs 93 (9%) 3·9
Ritonavir-boosted protease 
inhibitor + 2 or 3 NRTIs
126 (13%) 3·0
Unboosted protease inhibitor 
+ 2 or 3 NRTIs
270 (27%) 6·7
3 NRTIs 51 (5%) 4·8
(Continues on next page)
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Comparisons were made with adults heterosexually 
infected with HIV in COHERE (ie, excluding homosexual 
men), because this is the adult group that children with 
HIV are probably most similar to in terms of 
socioeconomic and migration status, and health seeking 
behaviour.20 Figure 1 shows the two inclusion criteria for 
initial ART regimens and deﬁ nitions of triple-class 
virological failure for the main analysis and the 
comparison of children with adults.
Statistical analysis
We used Kaplan-Meier and Cox regression methods to 
investigate the risk of triple-class virological failure after 
starting ART, and to compare the rate of failure in 
children with that in adults in the PLATO II project. 
Possible predictors of failure at the time of ART initiation 
were sex, age, year of ART initiation, initial drug regimen, 
previous ART exposure for prevention of mother-to-child 
transmission, AIDS diagnosis before ART, CD4 
percentages and viral load (within 6 months before ART 
initiation). Analyses were done with SAS software 
(version 9.1).
For children with triple-class virological failure who had 
failed a ritonavir-boosted protease inhibitor, we examined 
data from resistance tests done as part of routine care 
after the start of ART and up to 4 months after triple-class 
virological failure for a subset of cohorts where data were 
available. Major mutations from the International AIDS 
Society USA, 2008, mutation list were used to deﬁ ne 
resistance.23 Thymidine-associated mutations in HIV 
reverse transcriptase were deﬁ ned as M41L, D67N, K70R, 
L210W, T215Y, T215F, K219Q, and K219E.
Role of the funding source
The sponsors of the study had no role in the study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all the data in the study and had ﬁ nal 
responsibility for the decision to submit for publication.
Results
A total of 1007 children were identiﬁ ed in the 14 COHERE 
cohorts. The UK and Ireland, Spanish, Dutch, and French 
cohorts contributed more than 90% of children, with a 
smaller proportion from Denmark, Italy, Belgium, and 
the European Collaborative Study. Table 1 shows the 
characteristics of children at the time of ART initiation. 
Just over a third of children initiated ART in each of the 
calendar periods 1998–2000 and 2001–03, and a quarter 
in 2004–07. Fewer than 10% had been exposed to ART as 
part of prevention of mother-to-child transmission 
programmes; 55 were exposed to zidovudine only, and 
4 to NNRTIs. About 20% had a previous AIDS diagnosis. 
560 (56%) children initiated ART on a NNRTI-based 
regimen—232 (41%) on efavirenz and 328 (59%) on 
nevirapine. Most children starting ART with a ritonavir-
boosted protease inhibitor did so with lopinavir (94%; 
118 of 126).
Children were followed up for a median of 
4·2 (IQR 2·4–6·5) years and 932 (93%) of 1007 for at least 
12 months, with a median of 90 (56–112) days between 
viral-load measurements. 258 (26%) children interrupted 
ART at some time, of whom 158 (61%) restarted ART; 
most follow-up (93%) was of children on ART. Half 
Number of children (n=1007) Median follow-up person-years 
(Continued from previous page)
AIDS diagnosis before ART initiation
No 793 (79%) 3·7
Yes 214 (21%) 4·1
CD4 percentage at ART initiation
0–9% 193 (19%) 3·8
10–19% 254 (25%) 3·2
≥20% 236 (23%) 4·3
Unknown 324 (32%) 4·0
Median (IQR) 15·0 (9–24) ··
Viral load at ART initiation (log10 copies per mL)
0–4·49 181 (18%) 3·3
4·50-5·49 334 (33%) 3·4
≥5·50 258 (26%) 4·2
Unknown 234 (23%) 4·1
Median (IQR) 5·1 (4·6–5·7) ··
ART=antiretroviral therapy. IQR=inter-quartile range. NRTI=nucleoside or nucleotide reverse transcriptase inhibitors. 
NNRTI=non-NRTI. *Antiretroviral therapy (ART) for prevention of mother-to-child transmission was deﬁ ned as one or 
two antiretrovirals initiated within 7 days of birth and stopped up to 60 days after, or three or more antiretrovirals 
initiated within 7 days of birth and stopped up to 60 days after, and then no antiretrovirals for at least 90 days.
Table 1: Characteristics of children at the time of antiretroviral therapy initiation
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Figure 2: Incidence per 100 person-years (95% CI) of triple-class virological failure in children with HIV by 
duration of antiretroviral therapy
*At end of year 9.
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(518 [51%] of 1007) had ﬁ rst-line virological failure, with 
about 58% (95% CI 54–62) failure by 5 years after 
initiation of ART. Most children (470 [91%] of 518) had 
not started a third drug class at ﬁ rst virological failure; 
206 (44%) of 470 started a third drug class before the end 
of follow-up, with 55% (50–61) doing so by 5 years after 
ﬁ rst virological failure.
By the end of follow-up, 335 (33%) of 1007 children 
had started a third drug class, of whom 105 (10% overall 
and 44% of those with triple-class exposure) had 
developed triple-class virological failure. Nine (1%) died 
without such treatment failure. Incidence of triple-class 
virological failure during each year after ART initiation 
increased sharply in the ﬁ rst 2 years, from 0·5 per 
100 person-years (0·2–1·2) in the ﬁ rst year after ART 
initiation to 2·6 per 100 person-years (1·5–3·6) in the 
second year, and then rose more gradually up to the 
sixth year (4·0 per 100 person-years [2·1–7·0]; ﬁ gure 2). 
By 5 years after ART initiation the estimated cumulative 
proportion of children who had triple-class virological 
failure was 12·0% (9·4–14·6), and by 8 years it was 
20·3% (15·9–24·7). Redeﬁ nition of virological failure to 
6 months of continuous drug use rather than 4 months 
gave an estimated cumulative proportion of children 
with triple-class virological failure by 5 years of 9·4% 
(7·1–11·8%), and modiﬁ cation of the deﬁ nition to 
require conﬁ rmation of virological failure gave a 5-year 
proportion of 9·5% (7·2–11·8).
Older age (10–15 years) at the time of ART initiation 
was associated with an increased risk of failure (table 2). 
Univariate analyses Multivariate analyses
Hazard ratio 95% CI p Hazard ratio 95% CI p
Sex
Boy 1·0 ·· 0·96 1·0 ·· 0·92
Girl 1·0 0·7–1·5 ·· 1·0 0·7–1·5 ··
Age at start of ART (years)
<2 1·2 0·7–2·0 0·03 1·2 0·7–2·0 0·02
2–4 0·9 0·5–1·7 ·· 0·9 0·5–1·7 ··
5–9 1·0 ·· ·· 1·0 ·· ··
10–15 2·1 1·2–3·7 ·· 2·3 1·2–4·1 ··
Year of ART initiation
1998–2000 1·0 ·· 0·46 1·0 ·· 0·83
2001–2003 0·7 0·5–1·2 ·· 0·9 0·5–1·5 ··
2004–2007 0·9 0·4–2·0 ·· 1·0 0·4–2·4 ··
Initial regimen
NNRTI+2 NRTIs 1·0 ·· 0·46 1·0 ·· 0·24
NNRTI+3 NRTIs 0·7 0·3–1·6 ·· 0·7 0·3–1·6 ··
Ritonavir-boosted protease inhibitor + 2 or 3 NRTIs 0·5 0·2–1·4 ·· 0·4 0·1–1·3 ··
Unboosted protease inhibitor + 2 or 3 NRTIs 1·1 0·7–1·7 ·· 1·1 0·7–1·7 ··
3 NRTIs 0·8 0·3–2·1 ·· 0·8 0·3–2·0 ··
Previous ART exposure for prevention of mother-to-child transmission
No or unknown 1·0 ·· 0·91 ·· ·· 0·64
Yes 1·0 0·4–2·3 ·· 1·3 0·5–3·4 ·· 
AIDS diagnosis before ART initiation
No 1·0 ·· 0·18 1·0 ·· 0·12
Yes 1·3 0·9–2·1 ·· 1·4 0·9–2·3 ··
CD4 percentage at ART initiation 
0–9% 1·0 ·· 0·61 1·0 ·· 0·73
10–19% 0·9 0·5–1·7 ·· 1·0 0·6–1·9 ··
≥20% 0·8 0·4–1·5 ·· 0·9 0·5–1·8 ··
Unknown 1·1 0·7–1·9 ·· 1·3 0·7–2·4 ··
Viral load at ART initiation (log10 copies per mL)
0–4·49 0·65 0·3–1·2 0·58 0·5 0·3–1·0 0·24
4·50–5·49 1·0 ·· ·· 1·0 ·· ··
≥5·50 1·0 0·6–1·6 ·· 0·9 0·5–1·6 ··
Unknown 1·0 0·6–1·6 ·· 0·7 0·4–1·3 ··
ART=antiretroviral therapy. NRTI=nucleoside or nucleotide reverse transcriptase inhibitors. NNRTI=non-NRTI. 
Table 2: Predictors of triple class virological failure 
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Children with a previous AIDS diagnosis had a non-
signiﬁ cant trend towards an increased risk of triple-class 
virological failure (table 2). We recorded no signiﬁ cant 
diﬀ erence in the risk of failure by sex, year of ART 
initiation, type of initial ART regimen, previous ART 
exposure for prevention of mother-to-child transmission, 
or CD4 percentage or viral load at ART initiation.
Of the children with triple-class virological failure, 29 of 
105 never had a viral load measurement of less than 
500 copies per mL. Compared with the 76 who had at 
least one viral load measurement less than 
500 copies per mL before developing treatment failure, 
these children started ART at a younger age (median 1·8 
[IQR 0·5–4·4] vs 6·1 [1·2–10·1] years, p=0·008) and were 
triple-class exposed more quickly after starting ART 
(2·1 [1·4–3·8] vs 3·3 [1·9–4·6] years, p=0·018).
Of the 686 children starting ART with an initial regimen 
of two or three NRTIs and either a NNRTI or a ritonavir-
boosted protease inhibitor, 39 (6%) had triple-class 
virological failure (deﬁ ned as virological failure of two 
NRTIs, one NNRTI, and ritonavir-boosted protease 
inhibitor). The trend in the incidence of triple-class 
virological failure during each year after the start of ART 
was similar to the main analysis (data not shown), and by 
5 years after ART initiation the estimated cumulative 
proportion of children who had such failure according to 
this narrow deﬁ nition was 8·2% (95% CI 5·1–11·2). This 
proportion was signiﬁ cantly higher than that of adults 
heterosexually infected with HIV in the PLATO II 
project—4·2% (3·8–4·6), HR 2·2 (1·6–3·0, p<0·0001), 
adjusted for AIDS diagnosis before ART initiation and 
year of ART initiation. To explore the extent to which this 
raised risk of triple-class virological failure in children 
compared with adults was driven by treatment failure in 
older children and adolescents aged 10–15 years at ART 
initiation, we repeated this analysis, adjusted for AIDS 
diagnosis before ART initiation and year of ART initiation, 
for children aged 9 years or younger compared with 
adults; the HR was 1·7 (1·1–2·5, p=0·011).
Mutation data from resistance tests were available for 
40 (77%) children who had triple-class virological failure 
(81 tests). These tests detected mutations against NRTI 
in 26 of 36 children, mutations against NNRTIs in 
28 of 29, and mutations against protease inhibitors in 
0 of 15, while they took ART drugs of the corresponding 
class. M184V (17%), M41L (6), T215Y (6), and D67N (5) 
were the most common NRTI mutations; nine children 
had at least one thymidine-associated mutation. 
K103N (14), Y181C (13), and Y188L (6) were the most 
common NNRTI mutations.
Discussion
12% of children had triple-class virological failure after 
5 years on ART, and about a ﬁ fth had such treatment 
failure by 8 years on ART. Although these risks are low, 
and highlight the great success of antiretroviral treatment 
in children, they raise concerns about the proportion of 
children starting ART who are likely to maintain viral 
suppression for life, despite the potential availability of 
newer drugs from other classes (panel). The rate of triple-
class virological failure was highest in the ﬁ rst 2 years 
after ART initiation, rising gradually thereafter. After 
6 years on ART, the number of children with failure was 
small and the conﬁ dence intervals were wide, but the 
apparent decline in the rate of triple-class virological 
failure could also mirror early dropout of children who 
adhered most poorly to drug regimens, which is in line 
with our ﬁ nding that about a quarter of children with 
triple-class virological failure had never achieved 
virological suppression. This small group started ART at 
an earlier age and became triple-class exposed more 
quickly, raising the issue of adequate dosing in young 
children and presumably relating to very poor adherence 
by their caregivers.
Restriction of the analysis to children starting ART 
with two NRTIs and either a NNRTI or a boosted protease 
inhibitor and use of the same deﬁ nition of treatment 
failure showed that the overall rate of failure in children 
was over two-times higher than in adults with 
heterosexually transmitted HIV in COHERE. This 
increased rate of triple-class virological failure could be 
explained by lower virological suppression rates in 
children than in adults,19 absence of alternative regimens, 
adherence issues related to taste and formulation, a 
tendency for switches in regimen for children being 
delayed because of the need to manage adherence 
problems before switching treatment and hence 
switching regimen at high viral loads,24 and social factors, 
especially those that aﬀ ect adolescents.
As in the adult analysis,20 adolescents and young adults 
had the highest risk of triple-class virological failure. Drug 
adherence is a challenge for children and young people 
with any chronic disease. For those with HIV infection, 
there are additional factors, including coming to terms 
with disclosure of their HIV status, secrecy and guilt 
among adult family members, and dealing with HIV 
alongside their own sexual development. Fear of stigma 
increases their isolation and tendency towards denial, all of 
which might adversely aﬀ ect drug adherence. Although 
there are several studies of adherence to ART in children 
and young adults with HIV, most are small, hetero-
geneous—including both caregiver and child adherence 
measurements—and nearly all have been cross-sectional.25 
Murphy and colleagues16 reported a decline in adherence 
by teenagers over time associated with duration of ART, 
and Kekitiinwa and colleagues26 described poor responses 
to ART in newly diagnosed young people aged 10 years or 
older in the UK and Ireland.
However, when adolescents aged 10–15 years were 
excluded from the comparison with adults, the HR 
declined from 2·2 to 1·7, but remained signiﬁ cant. This 
ﬁ nding suggests that factors relating to young children, 
whose drugs are mainly given by caregivers, are also 
important and need to be considered. Few adherence 
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studies have diﬀ erentiated child and caregiver adherence 
or studied changes in adherence longitudinally with 
age. In addition to adherence, other complexities in 
treatment of children with HIV include dosing and 
pharmacokinetics of drugs, and palatability and 
tolerability of formulations, all of which vary substantially 
with age.27 All these factors might adversely aﬀ ect 
virological response and contribute to poorer responses 
in children than in adults.
We recorded no association between drug classes used 
in the initial regimen and triple-class virological failure, 
supporting the use of regimens containing either 
NNRTIs or protease inhibitors as ﬁ rst-line ART in 
accordance with the current guidelines.7–9 Although our 
study was a non-randomised comparison, the PENPACT-1 
trial28 of ART initiation with protease inhibitor versus 
NNRTI combination ART regimens, in children with 
HIV-1 infection who have not received ART, showed no 
signiﬁ cant virological, immunological, or clinical 
diﬀ erences between these two randomised arms at 
4 years after ART initiation; of note, PENPACT-1 included 
both boosted and unboosted protease inhibitors, as in the 
present study. Our results also suggest that the rate of 
triple-class virological failure was higher in children who 
had been diagnosed with AIDS before starting ART, 
compared with those without an AIDS diagnosis at ART 
initiation, supporting the current recommendations of 
ART initiation at higher CD4 counts than previously 
used, and before clinical disease progression.7–9 However, 
virological failure was not associated with CD4 percentage 
or viral load at ART initiation, unlike in adults with HIV,20 
and could be due in part to low power, but also to the 
longer time taken to attain a virological set-point after 
primary infection in children (about 5 years)29 than in 
adults. No association between virological failure and use 
of ART for prevention of mother-to-child transmission 
was seen, although numbers were small.
Virological failure to a drug class does not necessarily 
mean that no drugs from that class can successfully 
suppress the virus in the future, especially if no resistance 
mutations occurred. For children with resistance test 
data, we found that most children on a NRTI or a NNRTI 
had resistance mutations, implying loss of future drug 
options from these classes. By contrast, protease-inhibitor 
resistance was not seen, which is consistent with results 
from the linked adult study and a randomised trial in 
children.30,31 Because boosted protease inhibitors are now 
the standard of care for children with HIV,7–9 resistance to 
them is probably unusual in children failing a boosted 
protease-inhibitor regimen.32
Our results have implications for developing and 
developed countries. Increasingly, drugs from the 
original three classes are widely available, and our 
results provide encouragement that viral load 
suppression can be achieved and maintained for many 
years with use of these drugs. In adults, adherence to 
ART has proved to be at least as high in sub-Saharan 
Africa as it is in North America, supporting the fact that 
outcomes reported in developed countries are relevant 
for developing countries.33 However, regardless of 
setting, there will be a need for availability of newer 
drugs if children with HIV infection are to maintain 
viral suppression for suﬃ  cient durations to enable 
them to live as long as their uninfected peers. If options 
do become exhausted then it becomes important to 
understand the immunological and clinical con-
sequences of long-term virological failure on ART in 
children, as has been studied in adults.34 Such analyses 
are beyond the scope of this study and, in fact, there 
have not been large enough numbers of children in the 
PLATO II project in this situation to allow reliable 
conclusions to be drawn.
The rate of virological failure of the three original drug 
classes seen in this study shows the challenge of 
maintaining lifelong viral suppression in children who 
start ART much earlier in life than do adults. Further 
detailed analysis is needed to compare rates of switching 
to second-line ART and viral suppression on second-line 
ART between adults and children, and to compare the 
development of resistance, and to repeat this analysis 
once further follow-up time has accrued; there is 
continued need for strategies to promote optimum drug 
adherence in children, caregivers, and young people to 
minimise the likelihood of triple-class virological failure, 
and for development of suitable new drugs and 
formulations to optimise the treatment of children with 
treatment failure. Fixed drug combinations and 
simpliﬁ cation of strategies could be important ways to 
maintain treatment options while children move through 
adolescence and reach adulthood.
Panel: Research in context
Systematic review
Although reports of paediatric cohort studies have described 
triple-class virological failure among small numbers of 
children, no large cohort or cohort collaboration has 
undertaken a formal assessment of the incidence or 
consequences of triple-class failure and no randomised trials 
of children with triple-class failure have been done.
Interpretation
Our study shows that the rate of development of triple-class 
virological failure in children with HIV in Europe is low, which 
supports the high eﬃ  cacy of these drugs in children, but the 
rate is higher than in adults. These children will be receiving 
antiretroviral therapy for an entire lifetime, and these 
ﬁ ndings highlight the challenges in attainment of long-term 
viral suppression. Early identiﬁ cation of non-responders, 
adherence support, especially for older children and young 
people aged 13 years or older starting antiretroviral therapy, 
and simpliﬁ cation of antiretroviral strategies are all needed to 
attain and sustain virological suppression.
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